News & Events
Press Releases & Presentations
Salubris Biotherapeutics Presents Updated Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Society for Clinical Oncology
Salubris Biotherapeutics Announces Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Conference
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
ESMO 2025 Poster Presentation: A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs
ASCO Trial in Progress Poster Presentation: A Phase 1/2 Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer
AACR 2025 Poster Presentation: Development and Preclinical Evaluation of JK06, a Biparatopic ADC Against 5T4
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
Upcoming Events
Past Events
American Association for Cancer Research
2026/04/17
American Society of Clinical Oncology
2026/05/29
BIO International Convention
2026/06/22
Jefferies Global Healthcare Conference
2025/11/07
BioEurope
2025/11/03
TD Cowen 45th Annual Health Care Conference
2025/03/03
BIO Europe Spring
2025/03/17
Jefferies Global Healthcare Conference
2025/06/03
Archived Events
BIO-Europe
2024/11/04
Piper Sandler Virtual Cardio Day
2024/04/10
J.P. Morgan Healthcare Conference
2024/01/09
Cowen 43rd Annual Health Care Conference
2023/03/06